Antipodean Pharmaceuticals
CompanyNew Zealand
Antipodean Pharmaceuticals develops one asset, in phase 2 (mitoq in chronic hepatitis c). Mostly small molecule acting on Oxidative stress and ROS signalling; based in New Zealand.
- Assets
- 1
- Furthest
- Phase 2
- Trials
- 3
- Signals
- 0
Pipeline
1Mitochondria-targeted antioxidant that reduces mitochondrial oxidative stress.
Phase 2Small moleculeOxidative stress and ROS signallingchronic hepatitis cnon-alcoholic fatty liver disease
Full company profiles: pipeline, trials, funding and people.
See Pro- Evidence behind the mechanisms2
- Trials3
- Similar companies6
Updated 7 Oct 2026 · 8 sources